Advertisement

Topics

New study results provide evidence that Ofev® (nintedanib) slows progression of IPF beyond four years with consistent safety

08:04 EDT 15 Sep 2018 | Biotech 365

INPULSIS®-ON study indicates safety and efficacy of Ofev® (nintedanib) are maintained over the long term and consistent with prior findings from INPULSIS® trials1 Results from INPULSIS®-ON, the open-label extension from the two INPULSIS® Phase III trials, published in Lancet RespiratoryContinue reading

Cet article New study results provide evidence that Ofev® (nintedanib) slows progression of IPF beyond four years with consistent safety est apparu en premier sur Biotech 365.

Original Article: New study results provide evidence that Ofev® (nintedanib) slows progression of IPF beyond four years with consistent safety

NEXT ARTICLE

More From BioPortfolio on "New study results provide evidence that Ofev® (nintedanib) slows progression of IPF beyond four years with consistent safety"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Respiratory
Asthma COPD Cystic Fibrosis Pneumonia Pulmonary Medicine Respiratory Respiratory tract infections (RTIs) are any infection of the sinuses, throat, airways or lungs.  They're usually caused by viruses, but they can also ...